The ACME Laboratories Ltd. announced that their product "Chlorzoxazone 500 mg tablet" which was manufactured from Solid Dosage Unit (SDU-Unit 2) of the Company and submitted to US FDA, has been approved by US Food & Drug Administration (US FDA) as per the section 505 (j) of the Federal Food, Drug and Cosmetic Act (FD&C ACT). The company has also informed that this prestigious accreditation will enable them to export products to the US market.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
69.1 BDT | -1.14% | 0.00% | -18.71% |
1st Jan change | Capi. | |
---|---|---|
-18.71% | 133M | |
+26.47% | 664B | |
+27.37% | 567B | |
-6.33% | 354B | |
+19.35% | 330B | |
+4.23% | 286B | |
+13.45% | 234B | |
+4.80% | 199B | |
-10.22% | 196B | |
-4.04% | 148B |
- Stock Market
- Equities
- ACMELAB Stock
- News The ACME Laboratories Ltd.
- The ACME Laboratories Ltd. Announces US FDA approval for "Chlorzoxazone tablet" of the Company